Your browser doesn't support javascript.
Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story.
Bisceglia, Irma; Canale, Maria Laura; Gallucci, Giuseppina; Turazza, Fabio Maria; Lestuzzi, Chiara; Parrini, Iris; Russo, Giulia; Maurea, Nicola; Quagliariello, Vincenzo; Oliva, Stefano; Di Fusco, Stefania Angela; Lucà, Fabiana; Tarantini, Luigi; Trambaiolo, Paolo; Moreo, Antonella; Geraci, Giovanna; Gabrielli, Domenico; Gulizia, Michele Massimo; Oliva, Fabrizio; Colivicchi, Furio.
  • Bisceglia I; Integrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Canale ML; Cardiology Department, Nuovo Ospedale Versilia Lido di Camaiore Lucca, Camaiore, Italy.
  • Gallucci G; Cardio-Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
  • Turazza FM; Cardiology Department, National Cancer Institute Foundation, Milan, Italy.
  • Lestuzzi C; Azienda Sanitaria Friuli Occidentale (ASFO) Cardiac and Cardio-Oncologic Rehabilitation Service at Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.
  • Parrini I; Cardiology Department, Ospedale Mauriziano Umberto I, Turin, Italy.
  • Russo G; Cardiovascular and Sports Medicine Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) Trieste, Trieste, Italy.
  • Maurea N; Cardiology Department, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy.
  • Quagliariello V; Cardiology Department, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy.
  • Oliva S; Cardio-Oncology Department, Istituto Tumori Giovanni Paolo II, Bari, Italy.
  • Di Fusco SA; Clinical and Rehabilitation Cardiology Department, Ospedale San Filippo Neri, Rome, Italy.
  • Lucà F; Cardiology Department, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.
  • Tarantini L; Cardiology Department, Santa Maria Nuova Hospital, Reggio Emilia, Italy.
  • Trambaiolo P; Divisione di Cardiologia, Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio-Emilia, Reggio Emilia, Italy.
  • Moreo A; A. De Gasperis Cardio Center, Aziende Socio Sanitarie Territoriali (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Geraci G; Cardiology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.
  • Gabrielli D; Cardio-Thoracic-Vascular Department, San Camillo-Forlanini Hospital, Rome, Italy.
  • Gulizia MM; Cardiology Department, Garibaldi Hospital, Catania, Italy.
  • Oliva F; Dipartimento Cardiotoracovascolare, Cardiology 1-Cath Lab, Coronary Care Unit (CCU), ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Colivicchi F; Clinical and Rehabilitation Cardiology Department, Ospedale San Filippo Neri, Rome, Italy.
Front Cardiovasc Med ; 9: 821193, 2022.
Article in English | MEDLINE | ID: covidwho-2252290
ABSTRACT
The pathophysiology of some non-communicable diseases (NCDs) such as hypertension, cardiovascular disease (CVD), diabetes, and cancer includes an alteration of the endothelial function. COVID-19 is a pulmonary and vascular disease with a negative impact on patients whose damaged endothelium is particularly vulnerable. The peculiar SARS-CoV-2-induced "endothelitis" triggers an intriguing immune-thrombosis that affects both the venous and arterial vascular beds. An increased liability for infection and an increased likelihood of a worse outcome have been observed during the pandemic in patients with active cancer and in cancer survivors. "Overlapping commonalities" between COVID-19 and Cardio-Oncology have been described that include shared phenotypes of cardiovascular toxicities such as left ventricular dysfunction, ischemic syndromes, conduction disturbances, myocarditis, pericarditis and right ventricular failure; shared pathophysiologic mechanisms such as inflammation, release of cytokines, the renin-angiotensin-aldosterone-pathway, coagulation abnormalities, microthrombosis and endothelial dysfunction. For these features and for the catalyst role of NCDs (mainly CVD and cancer), we should refer to COVID-19 as a "syndemic." Another challenging issue is the persistence of the symptoms, the so-called "long COVID" whose pathogenesis is still uncertain it may be due to persistent multi-organ viral attacks or to an abnormal immune response. An intensive vaccination campaign is the most successful pharmacological weapon against SARS-CoV-2, but the increasing number of variants has reduced the efficacy of the vaccines in controlling SARS-CoV-2 infections. After a year of vaccinations we have also learned more about efficacy and side-effects of COVID-19 vaccines. An important byproduct of the COVID-19 pandemic has been the rapid expansion of telemedicine platforms across different care settings; this new modality of monitoring cancer patients may be useful even in a post pandemic era. In this paper we analyze the problems that the cardio-oncologists are facing in a pandemic scenario modified by the extensive vaccination campaign and add actionable recommendations derived from the ongoing studies and from the syndemic nature of the infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Long Covid / Vaccines / Variants Language: English Journal: Front Cardiovasc Med Year: 2022 Document Type: Article Affiliation country: Fcvm.2022.821193

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Long Covid / Vaccines / Variants Language: English Journal: Front Cardiovasc Med Year: 2022 Document Type: Article Affiliation country: Fcvm.2022.821193